HS
FULC icon

HighVista Strategies’s Fulcrum Therapeutics FULC Stock Holding History

HighVista Strategies’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-89,963
Closed -$1.59M – 89
2021
Q4 		$1.59M Buy
+89,963
New +$1.78M 1.27% 21

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighVista Strategies's FULC Position: Q1 2022 in Review

HighVista Strategies sold out of Fulcrum Therapeutics (FULC) in Q1 2022, closing a stake of 89,963 shares — an estimated $1.59M sold.

HighVista Strategies first reported a position in FULC in Q4 2021 and held it in 1 quarter. The position peaked at $1.59M in Q4 2021. 108 funds tracked by Wall St. Rank hold FULC as of Q1 2022.

  • HighVista Strategies reported no remaining Fulcrum Therapeutics position as of Q1 2022 after selling out during the quarter.
  • HighVista Strategies sold 89,963 Fulcrum Therapeutics shares in Q1 2022, an estimated $1.59M.
  • HighVista Strategies first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 1 quarter.
  • HighVista Strategies's Fulcrum Therapeutics position peaked at $1.59M in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2022.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.